Lundgren JR, Janus C, Jensen SBK, et al
Why GLP-1s Matter Now Obesity and metabolic disease are at the heart of todays global health crisis
Eli Lilly, the pharmaceutical company behind Retatrutide, has invested in a massive clinical trial program
The art of tissue-specific and disease-specific dosing may emerge in the not-too-distant future: Rather than using the current pharmacologic doses of GLP-1s to soak receptors throughout the body, we may learn how to apply much more tailored brush strokes to effectively treat, say, dementia or rheumatoid arthritis
Since they debuted, injectable GLP-1 drugs like Ozempic have been in high demand
The new menu just so happens to benefit the consumers that might want smaller portions that are on GLP-1 medications, Cardenas said